- Home
- KNSA vs CELC Comparison
KNSA vs CELC Comparison
Compare KNSA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | CELC |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KNSA | CELC |
|---|---|---|
| Price | $52.46 | $118.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $58.43 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 742.4K | 654.3K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $37.48 | N/A |
| Revenue Next Year | $17.87 | $720.19 |
| P/E Ratio | $71.19 | ★ N/A |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $25.71 | $9.64 |
| 52 Week High | $54.23 | $129.09 |
Technical Indicators
Market Signals| Indicator | KNSA | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 66.79 | 50.85 |
| Support Level | $40.67 | $99.38 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.20 | 7.17 |
| MACD | 0.68 | -0.44 |
| Stochastic Oscillator | 85.60 | 54.80 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.